BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...SVP of investor relations and corporate strategy. Nomura was a senior analyst covering biotechnology at Mizuho...
BioCentury | Sep 4, 2020
Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

...$1.4 billion.In an Aug. 11 research note, Mizuho’s...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

...Medicine Inc. (NASDAQ:EDIT) and the University of Tokyo. Mizuho...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...first day, and closed Friday at $26.94. Nkarta’s underwriters were Cowen, Evercore ISI, Stifel and Mizuho...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Capital Life Sciences, Commodore Capital, 3E Bioventures Capital, HBM Healthcare Investments, Lightchain Capital, Logos Capital, Mizuho...
BioCentury | Jan 3, 2020
Clinical News

As itacitinib stumbles in acute GvHD, Incyte turns to chronic setting

...on whether itacitinib can succeed in the chronic setting, which holds a larger market opportunity. Mizuho...
BioCentury | Dec 12, 2019
Financial News

Momenta, Forty Seven, Assembly push 2019 follow-on tally to $21.5B

...to 2.4 million shares at $16.499 a share. Underwriters were Jefferies, SVB Leerink, William Blair, Mizuho...
BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...Eugene Scavola as EVP, technical operations. He was a managing partner at PBM Capital Group. Mizuho...
...Suisse. Jonathan Block, Associate Editor iOmx Therapeutics AG BioSpecifics Technologies Corp. Poseida Therapeutics Inc. GenSight Biologics S.A. Lyra Therapeutics Inc. Verrica Pharmaceuticals Inc. Mizuho...
BioCentury | Sep 16, 2019
Financial News

Sept. 6 Financial Quick Takes: Turning Point, uniQure raise follow-ons; plus Autolus, Frequency, ADC

...up to $100 million through a listing underwritten by J.P. Morgan, Goldman Sachs, Cowen and Mizuho...
BioCentury | Jul 23, 2019
Financial News

Frequency raises $62M to fund Phase II of hearing loss therapy

...areas such as multiple sclerosis with its platform. New investors Deerfield Management, RTW Investments and Mizuho...
Items per page:
1 - 10 of 236
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...SVP of investor relations and corporate strategy. Nomura was a senior analyst covering biotechnology at Mizuho...
BioCentury | Sep 4, 2020
Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

...$1.4 billion.In an Aug. 11 research note, Mizuho’s...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

...Medicine Inc. (NASDAQ:EDIT) and the University of Tokyo. Mizuho...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...first day, and closed Friday at $26.94. Nkarta’s underwriters were Cowen, Evercore ISI, Stifel and Mizuho...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Capital Life Sciences, Commodore Capital, 3E Bioventures Capital, HBM Healthcare Investments, Lightchain Capital, Logos Capital, Mizuho...
BioCentury | Jan 3, 2020
Clinical News

As itacitinib stumbles in acute GvHD, Incyte turns to chronic setting

...on whether itacitinib can succeed in the chronic setting, which holds a larger market opportunity. Mizuho...
BioCentury | Dec 12, 2019
Financial News

Momenta, Forty Seven, Assembly push 2019 follow-on tally to $21.5B

...to 2.4 million shares at $16.499 a share. Underwriters were Jefferies, SVB Leerink, William Blair, Mizuho...
BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...Eugene Scavola as EVP, technical operations. He was a managing partner at PBM Capital Group. Mizuho...
...Suisse. Jonathan Block, Associate Editor iOmx Therapeutics AG BioSpecifics Technologies Corp. Poseida Therapeutics Inc. GenSight Biologics S.A. Lyra Therapeutics Inc. Verrica Pharmaceuticals Inc. Mizuho...
BioCentury | Sep 16, 2019
Financial News

Sept. 6 Financial Quick Takes: Turning Point, uniQure raise follow-ons; plus Autolus, Frequency, ADC

...up to $100 million through a listing underwritten by J.P. Morgan, Goldman Sachs, Cowen and Mizuho...
BioCentury | Jul 23, 2019
Financial News

Frequency raises $62M to fund Phase II of hearing loss therapy

...areas such as multiple sclerosis with its platform. New investors Deerfield Management, RTW Investments and Mizuho...
Items per page:
1 - 10 of 236